Tech Company Financing Transactions

Nucleai Funding Round

Nucleai closed a $33 million Series B investment round on 3/24/2022. Backers included Sanofi-Genzyme BioVentures, Section 32 and Debiopharm Diagnostics.

Transaction Overview

Company Name
Nucleai
Announced On
3/24/2022
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series B
Investors

Sanofi-Genzyme BioVentures (Lead Investor) (Cris De Luca)

Section 32 (Lead Investor) (Andrew Harrison)

Debiopharm Diagnostics (Tanja Dowe)

Fosun RZ Capital

Grove Ventures

Vertex Ventures

Proceeds Purpose
Nucleai plans to use the new funding to further develop its platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations (CROs), who are applying its technology throughout translational research, clinical trials, and novel applications for drug discovery.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1375 W Fulton Ave. 650
Chicago, IL 60607
USA
Phone
Undisclosed
Website
www.nucleai.ai
Email Address
[email protected]
Overview
We are transforming precision medicine with AI-powered pathology. Our team's work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.
Profile
Nucleai LinkedIn Company Profile
Social Media
Nucleai Company Twitter Account
Company News
Nucleai News
Facebook
Nucleai on Facebook
YouTube
Nucleai on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Avi Veidman
  Avi Veidman LinkedIn Profile  Avi Veidman Twitter Account  Avi Veidman News  Avi Veidman on Facebook
Chief Medical Officer
Ori Zelichov
  Ori Zelichov LinkedIn Profile  Ori Zelichov Twitter Account  Ori Zelichov News  Ori Zelichov on Facebook
Chief Operating Officer
Eliron Amir
  Eliron Amir LinkedIn Profile  Eliron Amir Twitter Account  Eliron Amir News  Eliron Amir on Facebook
Chief Technical Officer
Albert Achtenberg
  Albert Achtenberg LinkedIn Profile  Albert Achtenberg Twitter Account  Albert Achtenberg News  Albert Achtenberg on Facebook
VP - R & D
Lotan Chorev
  Lotan Chorev LinkedIn Profile  Lotan Chorev Twitter Account  Lotan Chorev News  Lotan Chorev on Facebook
VP - Sales
Jonathan Daniels
  Jonathan Daniels LinkedIn Profile  Jonathan Daniels Twitter Account  Jonathan Daniels News  Jonathan Daniels on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/24/2022: Precirix venture capital transaction
Next: 3/24/2022: Weglot venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document funding rounds that are announced publicly. VC transactions reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.